吲哚布芬与阿司匹林治疗急性脑梗死的比较研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the efficacy and safety of Indobufen and Aspirin in the treatment of acute cerebral infarction. Methods From July to October 2020, a total of 60 cases of cerebral infarction admitted to the Department of Neurology of Affiliated Hospital of Jinggangshan University were selected as the research objects, divide into the experimental group (30 cases) and the control group (30 cases) according to the random number table method. On the basis of general conventional treatment, the test group was given Indobufen tablets orally, and the control group was given Aspirin Enteric-coated Tablets. The treatment effects, laboratory indexes, neurological function and the incidence rate in safety evaluation index events of the two groups were compared. Results The total effective rate of treatment in the experimental group was higher than that in the control group, and the difference was statistically significant (P＜0.05).The platelet aggregation rates of adenosine diphosphate (ADP) and arachidonic acid (AA) in the experimental group after treatment were lower than those in the control group, the differences were statistically significant (P＜0.05). The score of neurological deficit after treatment in the experimental group was lower than that in the control group, and the difference was statistically significant (P＜0.05). The incidence of safety evaluation index events in the experimental group after treatment (53.3%) lower than the control group (73.4%), the difference was statistically significant (P＜0.05).Conclusion Compared with Aspirin, Indobufen can better improve the patient′s neurological function, the treatment effect and safety are higher, and a more satisfactory anti-platelet aggregation effect can be obtained.

Key words： Cerebral Infarction Indobufen Aspirin Evaluation of curative effect

Received: 28 April 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/50

[1]	周金凤.瑞芬太尼预处理对大鼠脑缺血再灌注损伤GFAP、MBP 表达的影响[D].南昌：南昌大学，2019.
[2]	Zhou M，Wang H，Zeng X，et al.Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet，2019，394（10204）：1145-1158.
[3]	刘怡，姜红菊.吲哚布芬与阿司匹林治疗急性冠脉综合征的疗效比较[J].实用医药杂志，2020，37（7）：616-618.
[4]	Lee JY，Sung KC.Comparison of aspirin and indobufen in healthy volunteers[J].Platelets，2016，27（2）：105-109.
[5]	潘小玉，张再伟，李虎.吲哚布芬治疗不稳定型心绞痛的有效性和安全性的 Meta 分析[J].医学信息，2020，33（14）：80-84.
[6]	罗东雷，郭靖涛，王文静.冠心病患者服用阿司匹林致胃炎伴糜烂加重换用吲哚布芬1 例[J].中国循证心血管医学杂志，2019，11（6）：752-753.
[7]	葛均波、徐永健、梅长林.内科学[M].8 版.北京：人民卫生出版社，2013.
[8]	刘鸣，贺茂林.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[9]	彭斌，吴波.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[10]	周有婷，侯倩，才鼎.银杏达莫联合氯吡格雷对缺血性脑卒中的临床疗效观察[J].中西医结合心脑血管病杂志，2019，17（20）：3202-3204.
[11]	POOLE A，KACER D，COOPER E，et al.Sustained Inhibition of Proliferative Response After Transient FGF Stimulation is Mediated by Interleukin 1 Signaling[J].J Cell Physiol，2016，231（3）：650-658.
[12]	毛娜娜，谢梅林，顾振纶.纳豆激酶对急性血瘀模型大鼠血液流变学及血小板聚集的影响[J].中成药，2009，31（5）：679-682.
[13]	Saeed SA，Rasheed H.Calcium-dependent synergistic interaction of platelet activating factor and epinephrine in human platelet aggre-gation[J].Acta Pharmacol Sin，2003，24（1）：31-36.
[14]	ROSATO A，CATALANO A，CAROCCI A，et al.In vitro interactions between anidulafungin and nonsteroidal antiinflammatory drugson biofilms of Candida spp[J].Bioorg Med Chem，2016，24（5）：1002-1005.
[15]	薛岚平，龙雅丽.银杏叶提取物对急性脑梗死患者血小板聚集率的影响[J].中西医结合心脑血管病杂志，2012，10（10）：1188-1189.
[16]	常琪.吲哚布芬片与氯吡格雷治疗急性缺血性脑血管病的临床比较[J].中外医疗，2015，34（24）：110-111.
[17]	刘芳，王建文.吲哚布芬作用机制及临床应用的研究现状[J].中国临床药理学杂志，2021，37（13）：1724-1727.
[19]	徐荣彬，杨俊，韩晟，孙凤，马军.吲哚布芬预防心脑血管事件效果和安全性的Meta 分析[J].中国循证心血管医学杂志，2017，9（05）：532-538.
[20]	邬义强.吲哚布芬与拜阿司匹林联合氯吡格雷治疗急性冠脉综合征的临床比较[J].中外医学研究，2020，18（32）：40-42.
[18]	Patrono C，Baigent C，Hirsh J，et al.Antiplatelet drugs：American College of Chest Physicians evidence-based clinical practice guidelines[J].CHEST Joumal，2008，133（6S）：199S-233S.